Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat RBD of SARS-CoV-2 spike protein protects mice against COVID-19
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
A safe and effective vaccine is urgently needed to control the unprecedented COVID-19 pandemic. Four adenovirus vectored vaccines expressing spike (S) protein have advanced into phase 3 trials, with three approved for use. Here, we generated several recombinant chimpanzee adenovirus (AdC7) vaccines expressing S, receptor-binding domain (RBD) or dimeric tandem-repeat RBD (RBD-tr2). We found vaccination via either intramuscular or intranasal route was highly immunogenic in mice to elicit both humoral and cellular (Th1-based) immune responses. AdC7-RBD-tr2 showed higher antibody responses compared with both AdC7-S and AdC7-RBD. Intranasal administration of AdC7-RBD-tr2 additionally induced mucosal immunity with neutralizing activity in bronchoalveolar lavage fluid. Either single-dose or two-dose mucosal administration of AdC7-RBD-tr2 protected mice against SARS-CoV-2 challenge, with undetectable subgenomic RNA in lung and relieved lung injury. These results support AdC7-RBD-tr2 as a promising COVID-19 vaccine candidate.
Article activity feed
-
SciScore for 10.1101/2021.02.05.429860: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Materials: Ethics statement: All animal experiments were approved by the Committee on the Ethics of Animal Experiments of the IMCAS, and conducted in compliance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the IMCAS Ethics Committee.
IRB: Materials: Ethics statement: All animal experiments were approved by the Committee on the Ethics of Animal Experiments of the IMCAS, and conducted in compliance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the IMCAS Ethics Committee.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Female … SciScore for 10.1101/2021.02.05.429860: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Materials: Ethics statement: All animal experiments were approved by the Committee on the Ethics of Animal Experiments of the IMCAS, and conducted in compliance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the IMCAS Ethics Committee.
IRB: Materials: Ethics statement: All animal experiments were approved by the Committee on the Ethics of Animal Experiments of the IMCAS, and conducted in compliance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the IMCAS Ethics Committee.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Female BALB/c mice at 6 to 8 weeks of age were immunized with 1 × 1011 vp of vaccine or sham control through the i.m. or i.n. route. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Protein samples were separated by 12% SDS-PAGE and analyzed by Western blotting with rabbit anti-RBD of SARS-CoV-2 polyclonal antibody. anti-RBDsuggested: NoneGoat anti-rabbit IgG-horseradish peroxidase (HRP) antibodies were used as secondary antibodies. anti-rabbit IgG-horseradish peroxidase (HRP)suggested: NonePlates were incubated with goat anti-mouse IgG-HRP antibody or goat anti-mouse IgA-HRP antibody and subsequently developed with 3,3’,5,5’-tetramethylbenzidine (TMB) substrate. anti-mouse IgG-HRPsuggested: Noneanti-mouse IgA-HRPsuggested: NoneThe cells were subsequently fixed and permeabilized in permeabilizing buffer (BD Biosciences, USA) and stained with anti-mouse anti-IFNγ (BioLegend), anti-TNFα (BioLegend), anti-IL-2 (BioLegend), anti-IL-4 (BioLegend) and anti-IL-10 (BioLegend) antibodies. anti-mouse anti-IFNγ ( BioLegend)suggested: Noneanti-TNFαsuggested: Noneanti-IL-2suggested: Noneanti-IL-4suggested: Noneanti-IL-10suggested: NoneBesides, tissue sections were stained with anti-SARS-CoV-2 nucleoprotein antibody (Sino Biological, China) to detect virus infection. anti-SARS-CoV-2 nucleoproteinsuggested: NoneExperimental Models: Cell Lines Sentences Resources These recombinant adenovirus genomes were linearized and transfected into HEK293 cells to rescue the recombinant adenovirus, which was further propagated and purified by cesium chloride density gradient centrifugation as previously described (88). HEK293suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)Western blot: HEK 293T cells were preplated in 6-well plate, followed by infected with 1 × 109 vp of AdC7-S, AdC7-RBD, AdC7-RBD-tr2 or AdC7-empty as sham control. HEK 293Tsuggested: NoneThen the mixture was transferred to pre-plated Huh7 cell monolayers in 96-well plates. Huh7suggested: NoneExperimental Models: Organisms/Strains Sentences Resources Animal protection against virus challenge: To evaluate the protection efficacy of vaccine candidates against SARS-CoV-2, a recombinant adenovirus Ad5-hACE2 transducing BALB/c mice model was used. BALB/csuggested: RRID:IMSR_ORNL:BALB/cRl)Software and Algorithms Sentences Resources The coding sequence was codon-optimized for mammalian cell expression and synthesized by GENEWIZ, China. GENEWIZsuggested: (GENEWIZ, RRID:SCR_003177)Graphs were generated with GraphPad Prism software. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
